BODHI TREE BIOTECHNOLOGY (BDTB) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BDTB SEC filings page.
BODHI TREE BIOTECHNOLOGY (BDTB) reported $17K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
The reported business is financed without liabilities, but overhead far exceeds revenue and losses closely track cash outflow.
Net loss of$150K nearly matched operating cash flow of-$150K , indicating that the reported loss was largely cash-based rather than mainly caused by noncash accounting charges.
With
Selling, general and administrative expense reached
Financial Health Signals
BODHI TREE BIOTECHNOLOGY does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BODHI TREE BIOTECHNOLOGY reported a net loss of $150K while operations used $150K of cash. With neither figure positive, the ratio between the two carries no quality signal.
BODHI TREE BIOTECHNOLOGY reported an operating loss of $148K against $2 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BODHI TREE BIOTECHNOLOGY generated $10K in revenue in Q3 2026. Against the prior quarter it is down 33.3%.
BODHI TREE BIOTECHNOLOGY reported -$23K in net income in Q3 2026. This represents a decrease of 11.6% from the same quarter a year earlier. Against the prior quarter it is up 20.6%.
Not reported for Q3 2026.
Cash & Balance Sheet
BODHI TREE BIOTECHNOLOGY held $4K in cash as of Q3 2026; long-term debt is not reported for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
BODHI TREE BIOTECHNOLOGY's ROE was -167.8% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 151.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 88.9 percentage points.
Not reported for Q3 2026.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
None of these metrics is reported for Q3 2026.
BDTB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10K | $15K | $0-100.0% | N/A | $0-100.0% | $0 | $5K | N/A |
| SG&A Expenses | $33K+66.2% | $43K-17.7% | $53K-24.1% | N/A | $20K+278.9% | $52K+44881.9% | $70K | N/A |
| Operating Income | -$23K-16.1% | -$28K+46.5% | -$53K+18.3% | N/A | -$20K-305.3% | -$52K-44881.9% | -$65K | N/A |
| Interest Expense | $10.0% | $2+100.0% | $1 | N/A | $1 | $1 | N/A | N/A |
| Income Tax | N/A | $1K+1.0% | N/A | N/A | $800 | $1K | N/A | N/A |
| Net Income | -$23K-11.6% | -$29K+45.4% | -$53K+18.3% | N/A | -$21K-313.5% | -$53K-45958.6% | -$65K | N/A |
| EPS (Basic) | $0.00 | $0.00 | -$0.01 | $0.00 | $0.00 | $0.00 | $0.00 | N/A |
| EPS (Diluted) | $0.00 | $0.00 | -$0.01 | $0.00 | $0.00 | $0.00 | $0.00 | N/A |
| Diluted Shares (Avg) | 25M0.0% | 25M0.0% | 25M0.0% | N/A | 25M+53.6% | 25M | 25M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, EBITDA.
BDTB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $18K-85.9% | $41K-73.1% | $70K | $119K-55.8% | $130K | $151K | N/A | $269K |
| Cash & Equivalents | $4K-96.7% | $23K-84.2% | $47K-75.6% | $109K-57.9% | $120K+71.3% | $144K+194.9% | $194K | $260K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5K | $4K | $4K | $0-100.0% | $0 | $0 | N/A | $500 |
| Current Liabilities | $5K | $4K | $4K | N/A | N/A | N/A | N/A | $500 |
| Non-Current Liabilities | $0 | $0 | $0 | N/A | N/A | N/A | N/A | $0 |
| Total Equity | $14K-89.4% | $37K-75.4% | $66K-67.6% | $119K-55.7% | $130K+117.8% | $151K+211.3% | $204K | $269K |
| Retained Earnings | -$317K-57.7% | -$294K-63.1% | -$265K | -$212K-241.6% | -$201K | -$180K | N/A | -$62K |
Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BDTB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
BDTB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -232.0% | -186.2% | N/A | N/A | N/A | N/A | -1295.5% | N/A |
| Net Margin | -231.9% | -194.6% | N/A | N/A | N/A | N/A | -1295.5% | N/A |
| Return on Equity | -167.8%-151.8pp | -78.9%-43.4pp | -80.0%-48.2pp | N/A | -16.0%-32.3pp | -35.5%-35.2pp | -31.8% | N/A |
| Return on Assets | -126.6%-110.6pp | -72.1%-36.6pp | -75.9% | N/A | -16.0% | -35.5% | N/A | N/A |
| Debt-to-Equity | 0.33+0.3x | 0.09+0.1x | 0.05 | 0.000.0x | 0.00 | 0.00 | N/A | 0.00 |
| Asset Turnover | 0.55+0.5x | 0.37+0.4x | 0.00 | N/A | 0.00 | 0.00 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Current Ratio, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Where BODHI TREE BIOTECHNOLOGY Ranks
Frequently Asked Questions
What is BODHI TREE BIOTECHNOLOGY's annual revenue?
BODHI TREE BIOTECHNOLOGY (BDTB) reported $17K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is BODHI TREE BIOTECHNOLOGY profitable?
No, BODHI TREE BIOTECHNOLOGY (BDTB) reported a net income of -$150K in fiscal year 2025.
What is BODHI TREE BIOTECHNOLOGY's return on equity (ROE)?
BODHI TREE BIOTECHNOLOGY (BDTB) has a return on equity of -125.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BODHI TREE BIOTECHNOLOGY's operating cash flow?
BODHI TREE BIOTECHNOLOGY (BDTB) recorded an outflow of $150K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BODHI TREE BIOTECHNOLOGY's total assets?
BODHI TREE BIOTECHNOLOGY (BDTB) had $119K in total assets as of fiscal year 2025, including both current and long-term assets.
What is BODHI TREE BIOTECHNOLOGY's debt-to-equity ratio?
BODHI TREE BIOTECHNOLOGY (BDTB) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BODHI TREE BIOTECHNOLOGY's return on assets (ROA)?
BODHI TREE BIOTECHNOLOGY (BDTB) had a return on assets of -125.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does BODHI TREE BIOTECHNOLOGY's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BODHI TREE BIOTECHNOLOGY (BDTB) held $109K in cash, cash equivalents and investments, and reported an operating cash outflow of $150K over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Are BODHI TREE BIOTECHNOLOGY's earnings high quality?
BODHI TREE BIOTECHNOLOGY (BDTB) reported a net loss of $150K while operations used $150K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BODHI TREE BIOTECHNOLOGY cover its interest payments?
BODHI TREE BIOTECHNOLOGY (BDTB) reported an operating loss of $148K against $2 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.